
CONTENTS

SECTION 1 HYPERTENSION

1. Pitfalls in Hypertension Management	3
K Tewary	
Errors in Examination	3
Diagnostic Errors	3
Treatment Errors	4
Errors by Patients	4
2. Ambulatory Blood Pressure Monitoring in Clinical Practice.....	6
Narayan G Deogaonkar, Viplav N Deogaonkar	
3. Azilsartan: A New Baby in Old Horizon	17
BA Muruganathan	
Evolution of the Angiotensin II Receptor Blockers	17
Angiotensin Receptor Blockers: Beyond Blood Pressure Lowering Effects	18
Tolerability	18
Direct AT1R Effects of Azilsartan	19
Azilsartan: Potent AT1 Receptor Binding	19
Azilsartan: Pleiotropic Effects Beyond BP Lowering	19
Azilsartan: Potential Effect in Cardio-Renal Protection	20
Summary of the Unique Features of Azilsartan	22
4. Hypertension and Menopause	24
Anuj Maheshwari, Shipra Kunwar	
Role of Oxidative Stress and Vasoconstrictors	24
Hypertension: The Key Risk Factor during Menopause	26
How should It be Treated?	27
5. Renovascular Hypertension: Current Status	28
Puneet Rijhwani	
Pathogenesis	28
Renovascular Hypertension: Major Causes	28
Diagnosis	29
Medical Management	30

Surgical Revascularization	31
Angioplasty	31
6. Diuretics for Hypertension: Review and Update.....	33
R Rajasekar	
Effect of Low Dose Diuretic	33
Types of Diuretics	33
Potassium-Sparing Common Combination Diuretics	35
Combination of Diuretic with Anti-HT Drugs	35
7. High Altitude Systemic Hypertension: Unraveling the Mystery	36
VA Kothiwale, Deebanshu Gupta	
Effects of High Altitude on Cardiovascular System	36
Need for Definition of HASH – and Its Prevalence	36
Pathophysiology of Hash	38
Role of Endothelin 1	40
Ageing, High Altitude and Blood Pressure-A Complex Relationship	41
Blood Pressure Changes with Aging	41
How BP Behaves with Aging in People Chronically Exposed to High Altitude	42
Importance of Recognizing Hash	42
Diagnosis of HASH	42
Treatment of HASH	42
8. Management of Isolated Systolic Hypertension: Current Concepts	44
Girish Mathur, Shrikant Chaudhary	
Prevalence and Risk Factor	44
Classification of ISH	45
Evaluation of ISH	45
Management of Hypertension	45
Benefits of Treatment of ISH	48
Interventional Trial Concerning ISH	48
Smaller Studies on ISH	48
9. Blood Pressure Control with Changing Time	50
BR Bansode	
Management of Hypertension	50
JNC 1974 to 2003 (1 to 7)	51
Conclusion and Perspectives	54

10. Management of Hypertension in Diabetes.....	55
BB Thakur, Smita Thakur	
Hypertension	55
Pharmacologic Treatment	58
Gestational Diabetes	61
11. Grey Areas in Diagnosis and Management of Hypertension.....	67
Anita Jaiswal	
Rule of Halves	67
Types of Blood Pressure Instruments	70

SECTION 2 CARDIOLOGY

12. Atherosclerosis: Can We Tame it?	75
Harendra Kumar	
Methods are Carotid Intima-Media Thickness (CIMT)	75
Cholesterol Absorption Inhibitor	77
13. Cardiac Cachexia	80
AKP Singh	
Pathophysiology	80
Anabolic Failure	80
Catabolic Activation	80
Insulin Resistance	80
Skeletal Muscle	81
14. Is Intervention Still Relevant in Stable CAD?	82
Santanu Guha, Bappaditya Kumar	
Management of Stable Coronary Artery Disease	82
Indications for PCI	83
Improvement in Survival with PCI	83
Relief of Angina	83
Patients without Clear Indications for Intervention	84
15. Newer Oral Anticoagulants in Clinical Practice	86
Anshul Kumar Jain	
Comparison of NOACs with VKA	86

16. Dual Antiplatelet Therapy: How Long?	90
Sameer Kumar, Girish MP, Mohit D Gupta	
What is the Debate? 90	
Risk Stratification 90	
Short-term versus Long Term DAPT: The Evidence So Far 91	
Duration of Dual Antiplatelet Therapy in Cases of Stable Coronary Artery Disease (CAD) After PCI 91	
Duration of Dual Antiplatelet Therapy in Patients Presenting with Acute Coronary Syndrome (ACS) 92	
Duration of DAPT in Patients Undergoing CABG 93	
Elective Noncardiac Surgery in Patients Treated with DAPT and PCI 93	
Switch Over Between Antiplatelets 94	
Special Circumstances 94	
17. Newer Biomarkers in Heart Failure	97
Saumitra Ray	
Diagnosis 97	
Other Biomarkers 98	
Biomarkers of HFpEF 98	
18. Coronary Microvascular Dysfunction: An Update	100
SM Mustafa Zaman	
Risk Factors and Pathophysiology 100	
Diagnosis 102	
Clinical Profile 102	
Treatment of Coronary Microvascular Dysfunction 104	
19. How did Fractional Flow Reserve Change My Clinical Decisions? Case-based Discussions	110
Nagendra Boopathy Senguttuvan	
Fractional Flow Reserve 110	
Characteristics of FFR 110	
Functional PCI 111	
Deferred PCI 112	
Assessment of Serial Lesions 112	
20. Mega Trials in Cardiology	115
Sundeep Mishra	
Hypertension Trials 115	
Secondary Prevention of CAD 116	
Hope Trial 116	
Arrhythmia 117	

Heart Failure	117
Diabetes Mellitus	118
21. Rheumatic Valvular Heart Disease	121
RR Singh	
Signs and Symptoms	121
Mitral Stenosis	122
Mitral Stenosis with Close-up on Mitral Valve	122
Medical Treatment	124
Surgical Treatment	124
22. Advances in Management of Pulmonary Arterial Hypertension	125
Abhishek Gupta, S Ramakrishnan	
Current Epidemiology	125
Management of PAH	125
Newly Approved Medications for PAH	126
Combination Therapy	127
Nonpharmacological Options	128
Stem Cell Therapy	128
Lung Transplantation	128
23. Infective Endocarditis: An Update	129
Sudhir Varma, Samman Verma, Rommel Singh	
Changing Epidemiological Profile	129
Diagnostic Issues	129
Antimicrobial Therapy	129
Complications	130
Indications for Surgery	131
Prevention	132
24. Pregnancy and Heart Disease	133
Gurleen Wander, Gurpreet Singh Wander	
Physiological Changes in Pregnancy	133
Peripartum Cardiomyopathy	134
Rheumatic Heart Disease	135
Prosthetic Heart Valves	135
Aortic Dissection	135
Congenital Heart Disease	136
General Principles of Management	136
Intrapartum	136

25. A Review of Cardiorenal Syndrome	138
Gurinder Mohan, Ranjeet Kaur, Aakash Aggarwal	
Pathophysiology	139
Biomarkers in Cardiorenal Syndrome	140
Management	141
26. Heart Failure with Reduced Ejection Fraction: Treatment Strategy	144
Amal Kumar Banerjee	
Classification	144
Diagnosis	145
Pharmacologic Treatment	147
Nonsurgical Device Treatment	147
Mechanical Circulatory Support and Heart Transplantation	148
Heart Failure and Comorbidities	149
Arrhythmias and Conductance Disturbances	149
Monitoring	149
27. Pulmonary Embolism: Focus on New Drugs	151
VK Katyal, Ashima Katyal, Naman Mukhi	
Pathophysiology	151
Clinical Presentations	151
Diagnosis	152
Management of Acute Pulmonary Embolism	153
28. Echocardiographic Navigation of AF from Irregular Pulse to Slurring of the Speech: Relevant at All Stages in India and the Real World	157
HK Chopra, Ravi R Kasliwal, Manish Bansal, Shraddha Ranjan	
Echocardiographic Navigation in AF Management	158

SECTION 3 DIABETES

29. ADA Standards of Care: An Update.....	173
Abhishek Pandey	
Section Changes	173
Staging of Type 1 Diabetes	174
Pharmacologic Therapy for Diabetes	175
30. Can Medical Care Change the Natural History of T2DM: Turning Fiction into Reality?	181
Rajesh Rajput	

31. Are all Gliptins the Same: How to Decide and Choose?	186
Harbir Kaur Rao, Rajinder Singh Gupta	
Pathogenesis of Type 2 Diabetes Mellitus	186
Ideal Antihyperglycemic Drug	187
Dipeptidyl Peptidase-4 Inhibitors	187
Efficacy	188
Safety	189
32. Diabetes and Inflammation	191
Jugal Kishor Sharma, Girish Khurana	
Link Between Diabetes and Inflammation	191
Clinical Implications of Inflammation in Type-2 Diabetes	195
Clinical Benefits Based on Inflammatory Theory	195
Drugs Related to the Endoplasmic Reticulum Stress Theory	195
33. Pollution and Diabetes: Is there a Link?	198
Brij Mohan	
Persistent Organic Pollutants	198
Air Pollutants Sources	200
34. Musculoskeletal Manifestations of Diabetes Mellitus.....	203
S Anita Nambiar, Divya G	
Limited Joint Mobility/ Rosenbloom Syndrome	203
Adhesive Capsulitis of the Shoulder	204
Dupuytren's Contracture/Disease	204
Hyperostosis	204
Carpal Tunnel Syndrome	204
Flexor Tenosynovitis	205
Neuroarthropathy (Charcot's Joints)	205
Diabetic Amyotrophy	205
Osteoporosis	205
Diabetic Muscle Infarction	205
Reflex Sympathetic Dystrophy	206
35. How to Hold the HOLD?	207
NK Singh, Vaibhav Agnihotri, Richa Singh Agnihotri	
Prevalence	207
Peculiarities of HOLD in India	207
Mechanistic Characteristics	208

Behavioral Modification	208
Physical Activity	209
Getting Rid of Persistent Organic Pollutants	209
Pharmacological Interventions	210
36. Dyslipidemia Management: Newer Avenues.....	211
Nirupam Prakash	
CETP Inhibitors	214
37. Metformin versus Insulin in Treatment of Gestational Diabetes Mellitus.....	217
Sandeep Garg, Onkar Awadhiya, Sunita Aggarwal	
Mechanism of Diabetes in pregnancy	217
Diagnosis of GDM	217
Glycemic Targets in GDM	218
Treatment Modalities of GDM	218
Comparison of Insulin versus Metformin in GDM	219
38. Early Initiation of Insulin Therapy in Diabetes Mellitus	221
Rajesh Kumar Jha, Sagar Dembla	
Concept and Evolution of Basal Insulin	221
Role of Insulin in Treatment of Type 2 Diabetes Mellitus	222
Benefits of Insulin Therapy in Diabetes Mellitus	222
Barriers to Basal Insulin in Type 2 Diabetes Mellitus	222
How to Start Insulin?	223
39. Diabetic Complications in Indian Scenario: An Update.....	225
Sidhartha Das, Santosh Kumar Swain, Saroj Kumar Tripathy	
Diabetes in India	225
Complications in Type 2 DM	226
Macrovascular Complications	226
Type 2 DM and Metabolic Syndrome	229
Microvascular Complications in Type 2 DM	229
Diabetic Retinopathy	230
Diabetic Neuropathy and Diabetic Foot	230
Other Complications in Type-2 DM	232
40. GLP-1 Analogs: Benefits Beyond Glycemic Control	238
Rajeev Chawla, Shalini Jaggi	
GLP-1 Analogs	239
Glycemic Efficacy of GLP-1 Receptor Agonists	241

Extra Glycemic Benefits of GLP-1 Analogs	241
Weight Loss Associated with the Use of GLP-1 Receptor Agonists	242
Side Effects and Associated Risks of GLP-1 Receptor Agonists	243
41. Gliptins versus Sulfonylureas: Which is Better?	247
V Palaniappen	
Importance of Glycemic Control in Curbing the Diabetes Burden	247
DM in Elderly Recommendation	259
Negative is not Absolutely Negative in SU Usage	261
Points in Favor of SU	261
42. Metformin—the Molecule of the Decade: Old is Gold	262
Sanjay Dash	
History	262
Mechanism of Action	262
Role of Metformin in T2DM	263
Metformin and Body Weight	263
Cancer Biology	264
Adverse Drug Reactions and Contraindications	264
43. A Decade of RCTs in Diabetes: Clinical Implications.....	266
Suhas Erande	
Prelude	266
2007: What Did We Know? DCCT EDIC UKPDS	266
2008: Tighter Glucose Control (?More Benefits)	266
Impact of Recent CVOT in Diabetes on Practice	267
Centrality of RCTS in Clinical Practice	267
Importance of Clinical Practice Guidelines	268
Factors which Influence Physician Practice	268
Have RCTS in Diabetes Helped Clinical Practice in Last Decade?	269
44. Insulin Pumps in India	270
Narendra Pal Jain, Rishu Bhanot	
Insulin Pumps in Type 2 in India	270
Types	271
Indications for an Insulin Pump	271
Current Scenario of Insulin Pumps in India	272

45. Newer Insulins and Art of Insulin Therapy	273
Mangesh Tiwaskar	
Science of Insulin Therapy: The Need	273
Insulins at a Glance	274
Modes of Insulin Delivery	275
Initiating Insulin Therapy	275
Overcoming the Psychological Barriers to Insulin Therapy	277
46. Individualization of Diabetes Care.....	281
KK Pareek, Girish Mathur	
Treatment Approaches for T2 Diabetes	281
Patient–Centered Approach	246
Implementation Strategies	284
Other Considerations	284
Therapeutic Patient Education	285
47. Diabetes and Immunity	286
Apurba Kumar Mukherjee, Indira Maisnam	
Immunity in the Pathogenesis of Diabetes Mellitus	286
Defective Immune Response in Diabetes Mellitus	288
48. Novel Therapeutic Approaches to Preserve Beta Cell Function in Diabetes Mellitus	290
Vijay Negalur	
Pancreatic Beta Cell Mass Function in Diabetes	290
Therapeutic Approaches to Preserve Beta Cell Function in T1D	291
Tumor Necrosis Factor- α (TNF- α) Agonist	293
Therapeutic Approaches to Preserve Beta Cell Function in T2D	293
49. Management of Diabetes in Resource Crunch Countries.....	299
G Prakash	
Prevalence	299
Challenges and the Way Ahead Epidemiological Data	299
Screening	299
Diabetes Management	300
Diabetes Education	300
Pharmacologic Management: Oral Antidiabetic Drugs	300
50. Exercise Prescription for Lifestyle Diseases: A Cornerstone	302
Anil Kumar Virmani	
Lifestyle Diseases	302

51. Nonhigh-Density Lipoprotein Cholesterol: Primary Target for Lipid Lowering 305

SN Narasingan

Non-HDL-C as an Indicator of ASCVD Risk 305

Other Advantages of Non-HDL-C 307

SECTION 4 ENDOCRINOLOGY**52. Growth Hormone Replacement Therapy: Current Recommendations..... 313**

Minal Mohit

Differences Between COGHD and AOGHD 314

Consequences of Untreated GHD 314

Metabolic Complications 314

Osteopenia/Osteoporosis 314

Quality of Life 315

Transitional Care of GHD 315

Diagnosis of GHD in Adults 315

Factors Affecting GH Dosing 316

Dosing Strategies 317

Safety Issues with GH Replacement Therapy 318

Unapproved Uses of GH in Adults 319

53. Vitamin D Therapy: Hope or Hype..... 326

PK Sasidharan

Vitamin D Basic Facts 326

Landmark Study on Vitamin D Deficiency 326

Reasons for Widespread Deficiency of Vitamin D 327

54. Approach to a Patient with Short Stature 333

Indira Maisnam

Physiology of Normal Growth 333

Patterns of Normal Growth 333

Diagnostic Approach to a Child with Short Stature 334

55. Logical Approach to Thyroid Nodule..... 337

KJ Shetty, KN Manohar

Clinical Presentation 337

Management 338

- 56. Primary Hypoparathyroidism and its Management..... 341**
 Ajay Aggarwal, Roopak Wadhwa
 Epidemiology 341
 Pathophysiology 341
 Signs and Symptoms 342
 Investigations 342
 Treatment 342
- 57. A New Look at Testosterone Therapy in Aging Males 344**
 DC Sharma
 Changes in Reproductive Hormones with Age 344
 Effects of Decrease in Testosterone 344
 Suggested Approach 345
- 58. Lipohypertrophy Secondary to Insulin Injection Therapy 347**
 Sunil Gupta
 Prevalence 347
 Definition of Lipohypertrophy 347
 Causes of Lipohypertrophy 347
 Diagnosis 348
 Clinical Consequences of Lipohypertrophy 348
 Management 350

SECTION 5 NEUROLOGY

- 59. Headache: Headache for Physician..... 355**
 Gurubax Singh
 Every Head has its Own Headache 355
 First Severe Headache 355
 Chronic Daily Headache 356
 Headache in Elderly 357
 Status Migranosus 357
 Menstrual Migraine 357
 Headache with Comorbidities 357
- 60. Approach to Multiple Cranial Nerve Palsy..... 359**
 K Mugundhan
 Intrinsic vs Extrinsic Brainstem Lesions 359

61. Nocturia: Evaluation and Management.....	363
Anish Kumar Gupta	
Clinical Presentation	363
Pathophysiology	363
Treatment	365
Multidisciplinary Management	366
62. Neuromyelitis Optica: A Physician's Perspective.....	367
Mrinal Kanti Roy, Sujoy Sarkar	
Epidemiology	367
63. First Seizure: Should or Should not be Treated?.....	371
PK Maheshwari, A Pandey, Akhilesh Kumar Singh	
Importance of Multiple Seizures	371
Is There any Role of Antiepileptic Drug Prophylaxis?	371
When to Initiate Antiepileptic Drugs?	372
Seizure Recurrence	372
Approach to a Case of First Seizure	373
Management of First Seizure	374
64. An Overview and Practical Clinical Hints in the Diagnosis of Temporal Lobe Epilepsy.....	376
Venkataraman Nagrajan	
Definition	376
Etiology	376
Pathology	376
Pathophysiology	376
Clinical Features	377
International Classification of the CPS	377
Seizure Phenomena	377
Eeg Phenomenon in TLE or CPS	378
Imaging Studies CT vs MRI	378
Differential Diagnosis	378
Management	379
Prognosis	379
65. Changing Scenario in Management of Status Epilepticus	380
Rajesh Shankar Iyer	
Changing Definitions and Classification	380
New Terminologies	381

Super-refractory Status Epilepticus	382
Treatment of Super-refractory SE: An Update	382
66. Present Status of Thrombolysis in Acute Ischemic Stroke: Indian Scenario	386
V Shankar	
Rates of Thrombolysis	386
Thrombolysis Outcomes	386
Thrombolysis Dosage	387
Sonothrombolysis	387
Tenecteplase	387
Telestroke	387
Complications and Other Observations	387
Intraarterial TPA	388
Thrombolysis and Endovascular Therapy	388
67. Immunomodulation in Neurological Disorders	389
Man Mohan Mehndiratta, Ashish Duggal	
Central Nervous System Disorders	389
Immunotherapy for MS Relapses	389
Disease-modifying Immunotherapy for MS	392
Myelin Oligodendrocyte Glycoprotein (MOG) Associated Demyelination	394
Acute Disseminated Encephalomyelitis	395
Primary Angiitis of CNS	398
Disease Affecting the Peripheral Nervous System	398
68. Vertigo: Clinical Approach and Management	404
Lakshmi Narasimhan Ranganathan, Tamil Pavai N, Guhan R, Arun Shivaraman MM, Mugundhan Krishnan	
Treatment of Vertigo	410

SECTION 6 GASTROENTEROLOGY/HEPATOLOGY

69. Acute Upper Gastrointestinal Bleeding	415
Rajesh Upadhyay, Deepak Sharma	
Etiology	415
Risk Factors	415
Clinical Presentation	416
Management	416

Medical Therapy	417
Endoscopic Therapy	417
Surgical Treatment	418
Angiographic Therapy	418
Prevention of Re-bleed	419
70. Acute Pancreatitis	421
G Loganathan, L Santhosh Vivekanadan	
Etiopathogenesis	421
Clinical Features, Diagnosis and Severity Prediction	423
Management	426
Beyond the Early Phase	428
Prevention	432
71. The Gut Microbiota: A Forgotten Organ	436
Balvir Singh, Ram Prakash Pandey, Mridul Chaturvedi, TP Singh, Ashish Gautam	
Composition of Gut Microbiota	436
Humans as Microbial Depots	436
Emergence of Microbiota	436
Gut Microbiota as an Organ	437
Link Between Gut Flora and Diseases	438
Future Hopes for Various Diseases	438
72. Nonalcoholic Fatty Liver Disease: Is it Really Benign?.....	442
AK Chauhan	
NAFLD is a Progressive Condition	442
Role of Metabolic Risk Factors in Disease Progression	443
Pathophysiologic Link of Metabolic Risk Factors with HCC	443
Extrahepatic Complications of Nafld	444
73. Glucose Metabolism Disorders in Chronic Liver Disease.....	446
Aparna Agrawal, Prashasti Gupta	
Role of Liver in Carbohydrate Metabolism	446
Glucose Metabolism in Diseased Liver	446
Mechanism of IR and GMD in CLD	446
Mechanism of LD in DM	447
Burden of GMD and IR in CLD and of LD in DM	447
Correlation of GMD with Etiology and Severity of CLD and Risk Factors of DM	447
Clinical Presentation of GMD in CLD	447

Implications of GMD on Complications of CLD	448
Diagnosis and Monitoring	448
Treatment of GMD in CLD	448
Results of Our Study	449
74. Hepatorenal Syndrome: Clinical Considerations	451
Tanuja Pravin Manohar	
Definition	451
Epidemiology	451
Pathophysiology	451
Precipitating Factors	452
Diagnosis	453
Diagnostic Criteria for Hepatorenal Syndrome	453
Preventive Measures	453
Biomarkers in HRS	453
Treatment	453
75. Cirrhosis of Liver: Beyond Beta-blockers and Diuretics	456
Anup K Das	
Variceal Hemorrhage	456
Hepatorenal Syndrome (HRS)	457
Spontaneous Bacterial Peritonitis (SBP)	457
76. Hepatitis B: Are We Moving Ahead Towards Cure?	463
Anil C Anand	
Epidemiology of HBV in India	463
The Virus	464
Immunopathogenesis	464
Natural History of HBV Infection	464
Management of Chronic HBV Infection and Innovative Approaches	465
Newer Drugs and Innovative Approaches	465
77. HIV/Hepatitis Coinfections	469
PK Agrawal	
Epidemiology	469
Pathogenesis	469
Treatment	470

78. Fecal Microbiota Transplantation: Current Indications and Methods..... 472

L Ilavarasi, SS Lakshmanan

Fecal Microbiota Transplantation Techniques 472

Donor Selection 472

History to be Obtained from the Donor 474

Stool Evaluation 474

Donor Blood Screening 474

Donor Stool Preparation: European Consensus 2017 474

Routes of Administration of FMT 474

Colonoscopy Guided 474

Upper GI Endoscopy Guidance 474

Clostridium Difficile Infections 474

Inflammatory Bowel Disease 475

Irritable Bowel Syndrome 475

FMT in Obesity/Insulin Resistance and Diabetes 475

FMT in Neurological Diseases 475

Current and Future Directions 475

SECTION 7 RESPIRATORY SYSTEM**79. Clinical Approach to a Patient of Dyspnea 481**

Alok Gupta, Rajat Gupta

Mechanism 481

Causes of Dyspnea 482

Assessment Of Dyspnea 487

History Taking 489

Physical Examination 489

Laboratory Studies 490

Advanced Studies 491

Management 493

80. Syndrome Z 495

Devendra Prasad Singh

OSA and Hypertension 495

Obesity 495

Insulin Resistance	495
Pathophysiology of Syndrome Z	495
Diagnosis of Syndrome Z	497
OSA: Clinical Features	497
OSAs and Hypertension	497
Lifestyle Modifications	498

81. Asthma COPD Overlap Syndrome..... 500

Kashinath Padhiary

Definition	500
Incidence	500
Pathogenesis	501
Contributing Factors	501
Clinical Features	501
Diagnosis	501
Prognosis	502
Treatment	502

82. Global Warming and its Health Impact..... 504

PS Shankar

Health Impact	504
Surface Temperature	504
El Nino	505
Ozone	505
Diseases	505
Future	506

83. ARDS: Recognition and Management..... 508

Niteen D Karnik, Priya Bhate

Recognition	508
Diagnosis	508
Management	508

84. Clinical Approach to Solitary Pulmonary Nodule 514

BNBM Prasad

Definition	514
Causes	514
Prevalence	515
Approach to Diagnosis	515
Management	521

85. Challenges in the Management of CAP 525

Prashant Prakash, Akhilesh Kumar Singh

Definition of CAP 525

Epidemiology and Etiology 525

Diagnosis of CAP 525

Role of Microbiological Investigations in CAP 526

General Investigations and Risk Stratification Required in Patients with CAP 528

Antimicrobial Therapy in CAP 529

86. Air Pollution and its Health Impact..... 533

Vishal Chopra, Prabhleen Kaur, Siddharth Chopra

Mechanisms Leading to Health Effects 533

Types of Pollutants 534

Effects of Air Pollution on Different Organs 534

SECTION 8 INFECTIONS**87. Infections Causing Cancer 539**

Anupam Dey

Pathogenesis 539

International Agency for Research on Cancer (WHO) Classification 539

Mechanisms by which Common Agents Cause Cancers 540

Detection and Proving Association of the Infectious Agent in Cancer 540

88. Transfusion Transmitted Infection 543

Apu Adhikary, Tuhin Santra

Human Immunodeficiency Virus 543

Hepatitis B virus 544

Hepatitis C virus 544

Malaria 544

Syphilis 544

Human T-Lymphotropic Virus I and II 544

Cytomegalovirus 545

Epstein-Barr virus 545

West Nile Virus 545

Parvovirus B19 545

Arboviruses 545

Bacterial infections 545

Other Infectious Agents	546
Pathogen Inactivation Technology	546
Donor Screening Questionnaire	546
89. Arboviral Infections: Is Effective Vaccination a Possible Solution?	547
Ashok Kumar, Shubha Laxmi Margekar, Venugopal Margekar	
Transmission	547
Clinical Findings and Epidemiology	548
Vaccination	548
Yellow Fever Vaccine	549
Japanese Encephalitis	549
Dengue Vaccine	550
Chikungunya Vaccine	551
Kyasanur Forest Disease	551
Crimean Congo Hemorrhagic Fever Virus	552
90. MDR-TB and XDR-TB: What are the Options?	553
Bidita Khandelwal	
Epidemiology	553
Defining MDR-, Pre-XDR- and XDR-TB	553
Management Options in M/XDR-TB	553
Regimes	554
Newer Drugs Options	554
High-Dose Isoniazid	555
Duration of Treatment M/XDR-TB	555
Surgical Options	555
91. Acute Encephalitis: Indian Scenario	556
Debasis Chakrabarti, Shankha S Sen	
Etiology	556
Epidemiology	556
92. Tropical Fever: A Case-based Approach.....	562
Manoranjan Behera, Sidhartha Das, Jayant Kumar Panda	
Specific Infections	564
Investigation Strategy	566
Treatment Strategy	566

93. Vivax Malaria: No Longer Benign!	570
K Nagesh	
Epidemiology	570
Malaria Parasite	571
Vivax Malaria	571
Malignant Behavior of <i>Plasmodium Vivax</i>	572
Pathophysiology	573
Clinical Features	573
Clinical Classifications	573
Management	574
Treatment of Malaria in Pregnancy	574
Clinical Malaria	575
94. Newer Modalities in Diagnosis of Tuberculosis	576
Prem Parkash Gupta	
Direct Sputum Smear Microscopic Examination	576
Culture-Based Methods for the Diagnosis of Tuberculosis	576
Rapid Detection of Drug Resistance: In-house Methods	577
Colorimetric Redox Indicator Methods	578
Diagnosis of TB Based on DNA Tools	578
Latent Tuberculous Infection Diagnosis	580
95. Resurgence of Yellow Fever: A Great Challenge	583
Rajib Ratna Chaudhary	
Transmission of Yellow Fever Virus	583
Pathogenesis	584
Clinical Presentation	584
Laboratory Finding	584
Differential Diagnosis	585
Treatment and Prevention	585
Prognosis	585
96. Complicated Dengue	586
Rajeev Gupta	
Introduction to Dengue	586
Hepatic Complications	587

97. Scrub Typhus: Need for Alert	588
Raman Sharma, Sunil Mahavar, Mayank Gupta	
Etiology	588
Epidemiology and Transmission	588
Clinical Manifestations	589
Diagnosis	590
Differential Diagnosis	590
Treatment	590
Prevention	591
98. Pyrexia of Unknown Origin: Current Concept	592
SV Ramana Murty, Chakravarthy DJK	
Epidemiology	592
99. Approach to a Patient of Meningitis.....	600
Sanjiv Maheshwari, Vijay Prakash Hawa	
Clinical Presentation	600
Examination	601
Investigation	602
CSF Examination	602
Other Laboratory Studies	603
Neuroimaging	603
Treatment	603
100. Leptospirosis: What We Should Know?	604
Shantanu Kumar Kar, Paluru Vijayachari, Jayant Kumar Panda	
Epidemiology	604
Clinical Presentation	605
Diagnosis	605
Treatment and Prevention	606
101. Kala-azar Elimination in India	607
Shyam Sundar	
102. Sick Cell Crisis: How to go Forward?	610
Srikant Kumar Dhar	
How to Diagnose?	610
How to Manage?	610
Principles of Management	611
Analgesia	611

Fluid Replacement	611
Treatment of Acute Chest Syndrome	611
Recommendations for Vaccination	613
103. Do Not Rash When Fever Coincides with Rash	614
Sriprasad Mohanty	
Approach to Diagnosis	614
Viral hemorrhagic Fevers	615
104. Disseminated Intravascular Coagulation: Management Updates	617
Puneet Saxena, Aradhna Sharma, Madhulata Agarwal, Sher Singh Dariya, Hitesh Sharma	
Pathogenesis	617
Diagnosis	618
Differential Diagnosis	619
Treatment	620
105. Adult Immunization: Current Scenario in India	622
Prasanta Kumar Bhattacharya, Subrahmanya Murti V	
Hepatitis B Vaccine	622
Hepatitis A Vaccine	624
Diphtheria, Pertussis and Tetanus Vaccines	624
Measles, Mumps and Rubella Vaccine	624
Varicella and Zoster (Shingles) Vaccines	624
Pneumococcal Vaccine	625
Meningococcal Vaccine	625
Haemophilus Influenzae Vaccine	626
Human Papilloma Virus Vaccine	626
Influenza Vaccine	626
Japanese Encephalitis Vaccine	626
Yellow Fever Vaccine	626
Cholera Vaccine	626
Typhoid Vaccine	626
Newer Vaccines	627
106. H1N1 Influenza: 9 Years' Journey in Gujarat	629
Asha N Shah	
History of Reassortment Events in the Evolution of the 2009 Influenza A (H1N1) Virus	629
Government of India Guidelines on Categorization of Seasonal Influenza A H1N1 Cases (Revised on 11-2-2015)	630
Cytokine Storm in Young	632

107. Ebola	636
Rajeev Raina, Nidhi Raina	
Background	636
Transmission	636
Clinical Symptoms	638
Diagnosis	639
Treatment and Vaccines	639
Lessons Learnt	639

SECTION 9 HUMAN IMMUNODEFICIENCY VIRUS

108. 90-90-90 Strategy in HIV Epidemic	645
R Sajith Kumar	
Treatment Target	645
Reaching Target 1	648
Reaching Target 2	648
Reaching Target 3	649
Ending the AIDS Epidemic	650
109. ART in HIV Infection: State-of-the-Art	652
BB Rewari, Manish Bamrotiya, Suman Singh	
Antiretroviral Therapy for HIV Infection	652
Goals of Antiretroviral Therapy	652
Clinical Pharmacology of Commonly used ARV Drugs	653
Considerations before Initiation of ART	654
Recommended Choice of First Line Regimen	656
Monitoring of Patients on ART	656
Treatment Failure: When to Change and What to Change	658
110. Opportunistic Infections in HIV: Changing Scenario	660
Amar R Pazare	
Common Opportunistic Infections in HIV-infected Patients in the Past	660
111. Neurological Manifestations of HIV	663
Dipanjan Bandyopadhyay, Amit Adhikary	
Acute Seroconversion Illness	663
Direct Viral Invasion	663
Myelopathy due to HIV	663

Peripheral Neuropathy	664
Opportunistic Infections Affecting the CNS	664
Progressive Multifocal Leukoencephalopathy	666
HIV Associated Malignancies Affecting the CNS	666
Neurological Disease Arising from ART	666
112. Cardiopulmonary Manifestations of HIV	667
Alaka K Deshpande	
Pericardial Disease	667
Cardiotoxic Drugs	668
Coronary Artery Disease	668
Pulmonary Manifestations	669
Bacterial Infections	669
Fungal Infections	670
Malignant Neoplasms	670
113. Immune Reconstitution Inflammatory Syndrome	671
Vinay Rampal	
Background	671
Definition	671
Clinical Factors Associated with the Development of IRIS	672
Mycobacterium Tuberculosis IRIS	673
Atypical Mycobacterial IRIS	674
Cytomegalovirus Infection IRIS	674
Varicella Zoster Virus Infection IRIS	675
Cryptococcus Neoformans Infection IRIS	675
Other Etiologies	676

SECTION 10 INTENSIVE CARE UNIT

114. Critical Care Toxicology: Update 2018	681
Omender Singh, Deven Juneja	
Initial Resuscitation and Management	681
Laboratory Investigations	682
Decontamination	682
Enhanced Elimination	682

115. Hypoglycemia in ICU	684
Sundaram Arulraj, Aarathy Kannan, Manikandan R, Vinodh Kumar A	
Classification of Hypoglycemia	684
Pathogenesis of Hypoglycemia in ICU	684
Acute Coronary Syndrome	690
116. Biomarkers in Sepsis.....	695
Virendra Kumar Goyal, Mohit Goyal	
C-reactive Protein	697
Biomarker Combinations	698
Statement of UNMET Need	698
117. Early and Empiric Antibiotics in Sepsis: Current Controversy	700
Trupti H Trivedi	
Future Therapy	703
118. Arterial Blood Gas Analysis: Simple Steps for Understanding	705
Ravindra Kumar Das	
Collection of Blood Samples and Transportation	705
Method of Analysis	705
Case History/Provisional Diagnosis	710
119. Superbugs in ICU and the Need for Antibiotic Stewardship.....	716
Pankaj Kumar	
120. Perioperative Management in Diabetes	720
Pramod Kumar Sinha	
Risks of Poor Diabetic Control	720
Factors Causing Adverse Outcome	720
Metabolic Response to Surgery and Anesthesia and the Effect of Diabetes	721
Principles and Target of Perioperative Management	721
Preoperative Measures	721
Intraoperative Management	722
Measures During Surgery	722
Postoperative Management	724
121. Hospital Acquired Infections.....	725
Piyush Jain	
Nosocomial Pneumonia	725
Diagnosis	726

Causative Organisms	726
Treatment	726
Preventive Measures	727
Nosocomial Urinary Tract Infections	727
Diagnosis	727
Treatment	727
Catheter Related Blood Stream Infection	728
Diagnosis	728
Treatment	728
Nosocomial Surgical Site and Soft Tissue Infection	728
Management	729

SECTION 11 TOXICOLOGY

122. Clinical Approach to Patient of Coma..... 733

Geeta Kampani, Umashankar US, Munish Prabhakar

Etiology and Pathogenesis	733
Assessment of COMA	733
History	733
General Physical Examination	733
Neurologic Examination	734
Brainstem Reflexes	735
Respiratory Patterns	735
Investigations	735
Prognosis	736

123. Common Poisoning and Management 737

Saurabh Srivastava

Aluminium Phosphide Poisoning (Celphos Poisoning)	737
Mechanism of Toxicity	737
Clinical Features of Intoxication	737
Organophosphate Poisoning	738
Mechanism of Toxicity	738
Clinical Features	738
Management	739
Corrosive Poisoning	739
Mechanism of Injury	739

Clinical Presentation	739
Management	740
Rodenticides	740
Zinc Phosphide	740
Anticoagulants	740
Kerosene Oil	740
Clinical Features of Intoxication	740
Management	740
Benzodiazepines	740
Clinical Features of Intoxication	740
Management	741

124. Management of Snake Bite in India..... 742

Shibendu Ghosh, Prabuddha Mukhopadhyay	
Snake Bite Prevention and Occupational Risk	744
Preventative Measures	744
Diagnosis Phase	744
General Signs and Symptoms of Viperine Envenomation	744
Late-onset Envenoming	747
Diagnosis Phase: Investigations	747
Management of Snake Bite in General	747
Handling Tourniquets	748
ASV Administration Criteria	748
Prevention of ASV Reactions: Prophylactic Regimes	749
Neurotoxic Envenomation	751
Recovery Phase	751
AntiHemostatic Maximum ASV Dosage Guidance	752

SECTION 12 HEMATOLOGY/ONCOLOGY

125. Stem Cell Therapy in Various Diseases: Dawn of a New Era 759

Sunita Aggarwal, Jahnvi Dhar, Sandeep Garg	
Stem Cell	759
Methods for Stem Cells Transplantation	759
Hematopoietic Stem Cell Transplantation (HSCT)	759
Scope of Stem Cell Therapy in India	761

126. Basics of Hematopoietic Stem Cell Transplant: Autologous and Allogeneic.....	763
Punit L Jain	
Principles of HSCT	763
127. Clinical Approach to Patient with Purpuric Spot.....	767
Chanchal Kumar Jana, Gaurab Bhaduri	
Pathophysiology	767
Causes of Nonpalpable Purpura	767
Causes of Palpable Purpura	768
Clinical Approach to Purpuric Spots	768
Case Studies	768
Diagnosis: Henoch–Schönlein Purpura	768
Diagnosis: Purpura Fulminans	769
Management of Some Common Causes of Purpura	769
128. Thrombocytosis: Clinical Approach.....	772
Sudhir Mehta, Laxmi Kant Goyal, Shaurya Mehta, Gunja Jain	
Regulation of Thrombopoiesis	772
Causes of Thrombocytosis	773
Clinical Features	775
Differential Diagnosis	775
Treatment	776
129. Macrophage Activation Syndrome.....	778
Tarun Kumar Dutta, Tony Kadavanu, Arunkumar Ramachandrappa	
Epidemiology	778
Etiopathogenesis and Triggers	778
Clinical Features	778
Laboratory Features	779
Diagnostic Criteria	781
Further Approach	781
Differential Diagnosis	781
Management	781
Biologicals	782
130. Hemotransfusion Therapy: Boon or Bane?.....	784
Anil Kumar Gupta	
Hemotherapy: A Precious Tool for Humans	784
Hemotherapy, Inherent Risks	785

131. Idiopathic CD4 Lymphocytopenia	788
Bhupendra Gupta, Harpreet Singh	
Pathogenesis	788
Clinical Manifestations	788
Infections	788
Evaluation	789
Diagnosis	789
Treatment	790
Other Treatment Modalities	790
Prognosis	790
132. Hepatocellular Carcinoma: Surveillance, Diagnosis and Management.....	791
Kirti Shetty	
Background	791
Surveillance Strategy	791
Target Population	791
Tests	791
Diagnosis	792
Tissue Diagnosis	792
Staging	792
Treatment	792
Surgical Therapies for HCC	793
133. Approach to a Patient with Polycythemia	795
Mathew Thomas	
Introduction, Definitions and Classification	795
Mechanisms	795
Major Causes of Polycythemia	796
Initial Evaluation of Patients with Polycythemia	796
Physical Examination	797
Systemic Examination	797
Laboratory Investigations	797
Further Diagnostic Approach	797
Further Evaluation	797
Diagnosis of Polycythemia Vera	798
Treatment of Polycythemia Vera	798
Management of Secondary Polycythemia	800

134. Immunotherapy: A New Weapon in Cancer Treatment 801

Vineet Talwar, Venkata Pradeep Babu K

Oncolytic Viruses in Immunotherapy 801

Vaccines in Immunotherapy 802

Adoptive Cell Therapy 802

Immune Check Point Blockade 802

135. Metronomic Chemotherapy in Metastatic Malignancies: A New Concept 805

Ankur Bahl

Metronomic Chemotherapy Versus Conventional Chemotherapy 805

Angiogenesis–Chemotherapy Model 806

Activation of Immunity 806

Rational of Various Drugs Used in Metronomic Chemotherapy 806

Metronomic Chemotherapy in Adult Cancers 807

Toxicity of Metronomic Chemotherapy 807

SECTION 13 RHEUMATOLOGY**136. Asymptomatic Hyperuricemia: What to Do? 811**

Arup Kumar Kundu, Shyamashis Das

Epidemiology 811

Definitions 811

Why Hyperuricemia Occurs? 811

Clinical Consequences of Persistent Hyperuricemia 812

Evaluation of Patients with Asymptomatic Hyperuricemia 813

When to Treat Asymptomatic Hyperuricemia? 813

137. Polyarteritis Nodosa: An Enigma 815

Ghan Shyam Pangtey, Paramjeet Singh

Case Vignette 815

Introduction 816

Epidemiology 817

Clinical Features 817

Laboratory Evaluation and Imaging 818

Prognosis 818

Management 819

- 138. Chikungunya Arthritis 821**
Harpreet Singh, Neeraj Kumar
- 139. Clinical Approach to a Patient with Vasculitis..... 825**
N Subramanian
Pathogenesis 825
Classification 825
Clinical Features 825
Investigations 827
Management 827
Practical Points 828
- 140. Osteoporosis Screening, Prevention, and Treatment..... 830**
Tanu Shweta Pandey
Osteopenia 830

SECTION 14 NEPHROLOGY

- 141. Recipient and Donor Selection for Renal Transplantation in India: Current Status 837**
Sanjay Kumar Agarwal
Advantages of Renal Transplant over Maintenance Dialysis 837
Contraindication of Renal Transplantation 837
Recipient Evaluation 837
Donor Evaluation 839
- 142. Rituximab: Panacea of Glomerular Diseases..... 842**
Dipankar M Bhowmik, N Rajkanna
Primary Glomerular Diseases 843
Glomerular Diseases that Cause Nephrotic Syndrome: Immune Complex 843
Secondary Glomerular Diseases 844
Adverse Effects of Rituximab 844
- 143. ABO-Incompatible Kidney Transplantation 846**
Dinesh Khullar, Sagar Gupta
Historical Perspective 846
ABO Antigens and Blood Groups 847
Pathogenesis 847
Accommodation 847

Techniques of Desensitization 847

Complications 848

144. Prevention and Management of Diabetic Kidney Disease..... 849

Pritam Gupta, Rajesh Aggarwal, Blessy Sehgal

Spectrum of Renal Involvement in Diabetes Mellitus (Type 2) 849

Risk Factors for the Development of Diabetic Nephropathy 849

Management of Microalbuminuria in Diabetes 851

Screening for Diabetic Kidney Disease 851

Other Biochemical Markers 851

Natural History of Type I Diabetic Nephropathy 851

Treatment Target 851

What is Optimal Target HBA_{1c}? 852

Blood Pressure Control 852

Blockade of Renin Angiotensin System 852

Treatment of Dyslipidemia in Diabetic Nephropathy 853

Emerging and Future Therapies 853

145. Anemia in Chronic Kidney Disease: Management..... 854

HK Aggarwal, Deepak Jain, Rahul Chauda

Anemia in Chronic Kidney Disease: Management 854

Diagnosis and Evaluation 854

Treatment 854

Erythropoiesis Stimulating Agents 855

Blood Transfusion 856

Other Therapies 856

Option in Future 857

SECTION 15 GERIATRICS AND GENETIC

146. Geriatric Teaching Indian Relevance 861

OP Sharma

Ageing 861

Medical Infrastructure 862

Geriatrics Services 862

Need v/s Availability 863

Need Based Solutions 863

147. Therapeutic Uses of Human Endothelial Progenitor Cells 865

Ananda Bagchi, Aradhya Sekhar Bagchi

Isolation of EPC 866

Therapeutic Uses of EPC 866

EPCs and Cardiovascular Risk factors 866

EPC and Atherosclerotic Cardiovascular Disease 867

EPCs and Cardiovascular Trials 868

Effect of Cardiac Drugs on EPCs 868

ACE Inhibitors and Angiotensin II Receptor Blockers 868

CD34 Antibody Coated Stents 868

Uses of EPCs in Diabetes Mellitus 869

Role of EPCs in Tumor Growth 869

Role EPCs in Endometriosis 869

Uses of EPCs in Wound Healing 869

Uses of EPCs in Peripheral Arterial Obstructive Disease 870

148. Management of Gender Dysphoric Persons, Sex Change Surgeries and Our (Indian) Experience 872

Richie Gupta, Rajat Gupta

149. Anemia in Elderly: Experience at a Large Tertiary Center..... 876

PS Ghalaut, Ragini Ghalaut

Classification of Anemia 876

Diagnosis of a Case with Anemia in Elderly 878

Investigations in Anemia in Elderly 878

Management of Anemia in Elderly 880

Indications of Blood Transfusion 881

SECTION 16 SOCIAL ISSUES**150. Medical Ethics 885**

Hem Shanker Sharma

Theories of Medical Ethics 885

Governing Bodies and Rules 887

151. Soul and Spiritual Health 888

SP Yoganna

Origin and Evolution of Universe—Matter and Energy theory (Big Bang Theory) 888

Natural Principles of Universe 888

Human is a Manifestation of Universal Energy 889

Human Being is the Miniature of the Universe 889

Human Being is Holistic 889

PreProgrammed Evolution and Human Body Functions 890

Life Energies 894

Soul (Atma) 895

Ways of Acquiring Spiritual Energy 897

God and God Men 898

What is Spiritual Health? 899

Diagnostic Approach 899

152. Cooking Oils: Which to Use? 901

Sonia Arora, Vitull K Gupta, Meghna Gupta

Composition of Fats 901

Trans Fatty Acids or Partially Hydrogenated Fatty Acids 902

What are Cooking Oils? 903

Choosing the Right Oil 904

Why Blends are Needed? 905

153. IT Solution in Regulation of Medical Education and Medical Practice..... 906

Ajay Kumar

SECTION 17 MISCELLANEOUS**154. Changing Trends in Medicine: Past, Present and Future 909**

Pritam Gupta, Ghan Shyam Pangtey, Sujata Mangla

Medicine Before the 20th Century 909

Medicine in the 20th Century 911

Medical Science and Technology in 21st Century 913

Future Medical Inventions 915

155. Isoniazid Preventive Therapy: Operational Guidelines.....	918
Mohanjeet Kaur, Ashish Chawla	
TB and HIV	918
HIV-TB Collaborative Activities	918
Single Window Services	918
Isoniazid Preventive Therapy	919
Why INH for IPT?	920
Evaluation of the Patients (Before Starting IPT)	920
Regimen Plan for IPT	920
Concomitant Use of IPT with ART	920
Can Co-Trimoxazole be Dispensed with IPT?	920
Drug Resistance with IPT	921
156. Hypnotherapy in Medical Disorders.....	922
Rajeev Mohan Kaushik	
Areas of the Brain Affected by Hypnosis	922
Physiological Effects of Hypnosis	923
Factors Affecting Therapeutic Response	923
Types of Hypnosis	923
Applications of Hypnotherapy in Medical Disorders	924
Hypnoanalysis	925
Prospects	925
157. An Approach to Recurrent Falls in the Elderly	926
S Ramnathan Iyer, Revati R Iyer	
158. Ultrasonography in Critically Ill Patients	929
Sameer Gulati, Bhupendra Gupta	
Equipment	929
Procedure: Lung Ultrasonography	929
Procedure: Compression Ultrasonography for Deep Vein Thrombosis	931
Procedure: Bedside Ocular Ultrasound	931
Procedure: Focussed Echocardiography	932
Procedure: Screening Abdominal Ultrasonography	933
Ultrasonography in Trauma	933
Advantages and Limitations	934

159. Imaging Parameters in Pulmonary Thromboembolism 935

Priya Jagia, Niraj Nirmal Pandey

Diagnosis of Pulmonary Embolism and Deep Venous Thrombosis 935

Imaging Modalities 935

Assessment of Pulmonary Embolism Severity and Prognostication 937

Diagnostic Algorithm in a Patient of Suspected PE 939

Index..... 941